Radius Health Company Profile (NASDAQ:RDUS)

About Radius Health (NASDAQ:RDUS)

Radius Health logoRadius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company's clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RDUS
  • CUSIP: N/A
  • Web: www.radiuspharm.com
Capitalization:
  • Market Cap: $1.53004 billion
  • Outstanding Shares: 43,504,000
Average Prices:
  • 50 Day Moving Avg: $36.80
  • 200 Day Moving Avg: $38.96
  • 52 Week Range: $31.58 - $59.22
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.81
  • P/E Growth: -0.14
Sales & Book Value:
  • Annual Revenue: $980,000.00
  • Price / Sales: 1,561.26
  • Book Value: $4.77 per share
  • Price / Book: 7.37
Profitability:
  • EBIDTA: ($225,190,000.00)
  • Return on Equity: -79.46%
  • Return on Assets: -71.59%
Debt:
  • Current Ratio: 7.04%
  • Quick Ratio: 6.99%
Misc:
  • Average Volume: 978,255 shs.
  • Beta: 1.35
  • Short Ratio: 9.34
 

Frequently Asked Questions for Radius Health (NASDAQ:RDUS)

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) posted its earnings results on Thursday, August, 3rd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.35) by $0.23. The firm earned $0.98 million during the quarter, compared to the consensus estimate of $1.96 million. During the same quarter last year, the firm earned ($1.01) earnings per share. View Radius Health's Earnings History.

Where is Radius Health's stock going? Where will Radius Health's stock price be in 2017?

7 brokerages have issued 1-year price targets for Radius Health's stock. Their predictions range from $24.00 to $85.00. On average, they expect Radius Health's stock price to reach $53.60 in the next twelve months. View Analyst Ratings for Radius Health.

What are analysts saying about Radius Health stock?

Here are some recent quotes from research analysts about Radius Health stock:

  • 1. According to Zacks Investment Research, "The company’s wider-than-expected loss in the second quarter was disappointing as expenses continue to increase with the launch of Tymlos. The FDA’s approval of Radius Health’s lead candidate, Tymlos, is a significant boost for the company. Although the osteoporosis market in the U.S. has a great potential as approximately 1.4 million postmenopausal women in the U.S. experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's Forteo and Amgen’s Prolia. Further, the company suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues to its MAA for Eladynos in Europe. While Radius' efforts in developing its pipeline are encouraging, we note that most of its candidates are in their early or mid stages of development. On a positive note, the company’ shares have outperformed the industry year to date." (8/8/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (7/31/2017)
  • 3. Cantor Fitzgerald analysts commented, "RDUS shares are rallying this morning (+2%) on FDA approval of TYMLOS (abaloparatide-SC) ahead of expectations, as the extended PDUFA was June." (4/28/2017)

Who are some of Radius Health's key competitors?

Who are Radius Health's key executives?

Radius Health's management team includes the folowing people:

  • Kurt C. Graves, Independent Chairman of the Board
  • Jesper Hoiland, President, Chief Executive Officer, Director
  • Jose Carmona, Chief Financial Officer, Principal Accounting Officer, Treasurer
  • Gary Hattersley Ph.D., Senior Vice President, Chief Scientific Officer
  • Brent Hatzis-Schoch, Senior Vice President, General Counsel, Secretary
  • Lorraine A. Fitzpatrick M.D., Chief Medical Officer
  • David P. Snow, Chief Commercial Officer
  • Gregory Williams Ph.D., Chief Development Officer
  • Alan H. Auerbach, Independent Director
  • Willard H. Dere M.D., Independent Director

Who owns Radius Health stock?

Radius Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (12.00%), BB Biotech AG (11.62%), MPM Asset Management LLC (8.96%), Farallon Capital Management LLC (8.47%), Vanguard Group Inc. (7.25%) and BlackRock Inc. (6.67%). Company insiders that own Radius Health stock include Gary Hattersley, Growth N V Biotech, Jesper Hoiland, Jose Carmona and Rob Ward. View Institutional Ownership Trends for Radius Health.

Who sold Radius Health stock? Who is selling Radius Health stock?

Radius Health's stock was sold by a variety of institutional investors in the last quarter, including Bain Capital Public Equity Management LLC, FMR LLC, OxFORD Asset Management LLP, Wells Fargo & Company MN, JPMorgan Chase & Co., Fiera Capital Corp, Bank of Nova Scotia and Alliancebernstein L.P.. View Insider Buying and Selling for Radius Health.

Who bought Radius Health stock? Who is buying Radius Health stock?

Radius Health's stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, TimesSquare Capital Management LLC, BB Biotech AG, RA Capital Management LLC, BlackRock Inc., State Street Corp, Vanguard Group Inc. and Capital Fund Management S.A.. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Insider Buying and Selling for Radius Health.

How do I buy Radius Health stock?

Shares of Radius Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Radius Health's stock price today?

One share of Radius Health stock can currently be purchased for approximately $35.17.


MarketBeat Community Rating for Radius Health (NASDAQ RDUS)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  396
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Radius Health (NASDAQ:RDUS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $53.60 (52.40% upside)

Analysts' Ratings History for Radius Health (NASDAQ:RDUS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017Jefferies Group LLCReiterated RatingHold$34.00 -> $38.00HighView Rating Details
7/31/2017Canaccord GenuitySet Price TargetBuy$85.00MediumView Rating Details
7/23/2017Cantor FitzgeraldSet Price TargetBuy$58.00MediumView Rating Details
5/24/2017Maxim GroupSet Price TargetSell$24.00LowView Rating Details
5/15/2017HC WainwrightReiterated RatingBuy$63.00LowView Rating Details
5/2/2017Cowen and CompanyDowngradeOutperform -> Market PerformLowView Rating Details
3/11/2017J P Morgan Chase & CoReiterated RatingBuyMediumView Rating Details
3/30/2016Goldman Sachs Group IncInitiated CoverageNeutral$37.00N/AView Rating Details
1/25/2016Bank of America CorporationReiterated RatingBuy$89.00N/AView Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Radius Health (NASDAQ:RDUS)
Earnings by Quarter for Radius Health (NASDAQ:RDUS)
Earnings History by Quarter for Radius Health (NASDAQ RDUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($1.35)($1.58)$1.96 million$0.98 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.18)($1.32)ViewListenView Earnings Details
2/23/2017Q416($1.34)($1.22)ViewN/AView Earnings Details
11/3/2016Q316($1.03)($1.07)$0.75 millionViewN/AView Earnings Details
8/4/2016Q216($0.95)($1.01)ViewN/AView Earnings Details
5/5/2016Q116($0.74)($0.94)ViewN/AView Earnings Details
2/25/2016Q415($0.64)($0.77)ViewListenView Earnings Details
11/5/2015Q315($0.58)($0.68)ViewN/AView Earnings Details
8/6/2015Q215($0.52)($0.61)ViewN/AView Earnings Details
5/6/2015Q115($0.52)($0.47)ViewN/AView Earnings Details
3/10/2015Q414($0.63)($0.55)ViewN/AView Earnings Details
11/10/2014Q314($0.65)($0.59)ViewN/AView Earnings Details
8/12/2014Q2($0.89)($2.22)$16.24 million$10.62 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Radius Health (NASDAQ:RDUS)
2017 EPS Consensus Estimate: ($4.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.94)($0.94)($0.94)
Q2 20171($1.37)($1.37)($1.37)
Q3 20171($1.31)($1.31)($1.31)
Q4 20171($1.20)($1.20)($1.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Radius Health (NASDAQ:RDUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Radius Health (NASDAQ:RDUS)
Insider Ownership Percentage: 15.00%
Insider Trades by Quarter for Radius Health (NASDAQ:RDUS)
Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)
Insider Trades by Quarter for Radius Health (NASDAQ:RDUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Jesper HoilandInsiderBuy6,100$32.72$199,592.00View SEC Filing  
9/14/2017Growth N V BiotechMajor ShareholderBuy150,000$33.45$5,017,500.00View SEC Filing  
9/14/2017Jose CarmonaCFOBuy3,000$32.83$98,490.00View SEC Filing  
9/12/2017Growth N V BiotechMajor ShareholderBuy50,000$35.42$1,771,000.00View SEC Filing  
9/5/2017Growth N V BiotechMajor ShareholderBuy50,000$36.75$1,837,500.00View SEC Filing  
8/16/2017Growth N V BiotechMajor ShareholderBuy60,000$35.98$2,158,800.00View SEC Filing  
8/10/2017Growth N V BiotechMajor ShareholderBuy150,000$34.97$5,245,500.00View SEC Filing  
5/30/2017Growth N V BiotechMajor ShareholderBuy40,000$34.21$1,368,400.00View SEC Filing  
5/25/2017Growth N V BiotechMajor ShareholderBuy40,000$36.25$1,450,000.00View SEC Filing  
5/18/2017Growth N V BiotechMajor ShareholderBuy50,000$34.41$1,720,500.00View SEC Filing  
5/17/2017Growth N V BiotechMajor ShareholderBuy35,000$33.44$1,170,400.00View SEC Filing  
5/12/2017Growth N V BiotechMajor ShareholderBuy15,000$34.00$510,000.00View SEC Filing  
5/9/2017Growth N V BiotechMajor ShareholderBuy50,000$35.93$1,796,500.00View SEC Filing  
5/8/2017Growth N V BiotechMajor ShareholderBuy43,400$35.57$1,543,738.00View SEC Filing  
5/2/2017Growth N V BiotechMajor ShareholderBuy75,000$33.91$2,543,250.00View SEC Filing  
5/1/2017Growth N V BiotechMajor ShareholderBuy150,000$35.39$5,308,500.00View SEC Filing  
3/21/2017Growth N V BiotechMajor ShareholderBuy50,000$35.83$1,791,500.00View SEC Filing  
3/17/2017Growth N V BiotechMajor ShareholderBuy30,000$38.41$1,152,300.00View SEC Filing  
3/15/2017Growth N V BiotechMajor ShareholderBuy61,721$39.97$2,466,988.37View SEC Filing  
3/10/2017Growth N V BiotechMajor ShareholderBuy38,279$39.17$1,499,388.43View SEC Filing  
1/22/2016Growth N V BiotechMajor ShareholderBuy38,259$31.67$1,211,662.53View SEC Filing  
1/13/2016Growth N V BiotechMajor ShareholderBuy50,000$39.90$1,995,000.00View SEC Filing  
11/12/2015Gary HattersleyinsiderSell5,683$75.00$426,225.00View SEC Filing  
11/3/2015Gary HattersleyinsiderSell13,333$70.00$933,310.00View SEC Filing  
10/23/2015Gary HattersleyinsiderSell11,302$65.00$734,630.00View SEC Filing  
10/21/2015Gary HattersleyinsiderSell1,501$65.36$98,105.36View SEC Filing  
10/21/2015Rob WardCEOSell50,000$61.99$3,099,500.00View SEC Filing  
8/21/2015Growth N. V. Biotechmajor shareholderBuy100,000$64.00$6,400,000.00View SEC Filing  
8/17/2015Kurt GravesDirectorSell22,694$70.00$1,588,580.00View SEC Filing  
7/6/2015Kurt GravesDirectorSell25,000$69.48$1,737,000.00View SEC Filing  
6/18/2015Kurt GravesDirectorSell25,000$55.05$1,376,250.00View SEC Filing  
5/1/2015Growth N V BiotechMajor ShareholderBuy50,000$36.46$1,823,000.00View SEC Filing  
4/29/2015Growth N V BiotechMajor ShareholderBuy50,000$36.23$1,811,500.00View SEC Filing  
4/28/2015Growth N V BiotechMajor ShareholderBuy50,000$36.59$1,829,500.00View SEC Filing  
4/27/2015Growth N V BiotechMajor ShareholderBuy50,000$38.38$1,919,000.00View SEC Filing  
3/6/2015Growth N V BiotechMajor ShareholderBuy75,000$47.08$3,531,000.00View SEC Filing  
2/25/2015Growth N V BiotechMajor ShareholderBuy35,000$45.74$1,600,900.00View SEC Filing  
6/11/2014Morana Jovan-EmbiricosDirectorBuy587,500$8.00$4,700,000.00View SEC Filing  
6/6/2014Growth N V BiotechMajor ShareholderBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Radius Health (NASDAQ:RDUS)
Latest Headlines for Radius Health (NASDAQ:RDUS)
Source:
DateHeadline
seekingalpha.com logoRadius Health (RDUS) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 25 at 4:34 PM
globenewswire.com logoRadius Health to Present at Cantor Annual Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 22 at 9:06 PM
finance.yahoo.com logoRadius Health to Present at Cantor Annual Global Healthcare Conference
finance.yahoo.com - September 22 at 9:06 PM
nasdaq.com logoRadius Health is Now Oversold (RDUS)
www.nasdaq.com - September 20 at 8:15 AM
nasdaq.com logoRadius Health Inc (RDUS) President and CEO Jesper Hoiland Bought $199592 of Shares - Nasdaq
www.nasdaq.com - September 17 at 7:17 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 11:02 AM
finance.yahoo.com logoRadius Health Inc (RDUS) President and CEO Jesper Hoiland Bought $199,592 of Shares
finance.yahoo.com - September 16 at 1:40 AM
americanbankingnews.com logoJose Carmona Acquires 3,000 Shares of Radius Health, Inc. (RDUS) Stock
www.americanbankingnews.com - September 15 at 4:32 PM
americanbankingnews.com logoJesper Hoiland Acquires 6,100 Shares of Radius Health, Inc. (RDUS) Stock
www.americanbankingnews.com - September 15 at 4:30 PM
americanbankingnews.com logoGrowth N. V. Biotech Acquires 150,000 Shares of Radius Health, Inc. (RDUS) Stock
www.americanbankingnews.com - September 15 at 4:30 PM
seekingalpha.com logoBiotech Forum Daily Digest: Revisiting Radius Health - Seeking Alpha
seekingalpha.com - September 15 at 3:30 PM
seekingalpha.com logoRadius Health (RDUS) Presents At Morgan Stanley 15th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - September 15 at 8:04 AM
seekingalpha.com logoRadius Health (RDUS) Presents at Morgan Stanley 15th Annual Global Healthcare Conference (Transcript) - Seeking Alpha
seekingalpha.com - September 13 at 8:38 PM
americanbankingnews.com logoInsider Buying: Radius Health, Inc. (RDUS) Major Shareholder Purchases 50,000 Shares of Stock
www.americanbankingnews.com - September 13 at 7:16 PM
globenewswire.com logoRadius Health Presents Positive Data for TYMLOS™ (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR ... - GlobeNewswire (press release)
globenewswire.com - September 11 at 6:17 AM
americanbankingnews.com logoInsider Buying: Radius Health, Inc. (RDUS) Major Shareholder Acquires 50,000 Shares of Stock
www.americanbankingnews.com - September 7 at 4:24 PM
finance.yahoo.com logoRadius Health to Present at Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - September 7 at 8:17 AM
finance.yahoo.com logoRadius Health (RDUS) Down 12.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 5 at 5:47 AM
streetinsider.com logoRadius Health (RDUS) to Present Eight Abstracts at ASBMR Including Results of ACTIVE and ACTIVExtend Trials for TYMLOS Injection
www.streetinsider.com - September 3 at 6:12 AM
streetinsider.com logoRadius Health (RDUS) to Present Eight Abstracts at ASBMR ... - StreetInsider.com
www.streetinsider.com - September 2 at 8:00 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Radius Health, Inc. (RDUS) Will Announce Quarterly Sales of $15.90 Million
www.americanbankingnews.com - August 29 at 11:22 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Expected to Announce Earnings of -$1.28 Per Share
www.americanbankingnews.com - August 27 at 6:18 AM
nasdaq.com logoFirst Week of RDUS April 2018 Options Trading
www.nasdaq.com - August 26 at 8:46 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 22 at 11:12 AM
finance.yahoo.com logoRadius Health, Inc. – Value Analysis (NASDAQ:RDUS) : August 19, 2017
finance.yahoo.com - August 19 at 6:55 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Major Shareholder Acquires $2,158,800.00 in Stock
www.americanbankingnews.com - August 18 at 1:22 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Radius Health Inc.
finance.yahoo.com - August 17 at 7:16 AM
americanbankingnews.com logoRadius Health, Inc. (NASDAQ:RDUS) Cut to Sell at BidaskClub
www.americanbankingnews.com - August 13 at 12:10 AM
americanbankingnews.com logoGrowth N. V. Biotech Buys 150,000 Shares of Radius Health, Inc. (RDUS) Stock
www.americanbankingnews.com - August 11 at 1:22 PM
seekingalpha.com logoRadius Health (RDUS) Presents At Canaccord Genuity 37th Annual Growth Conference - Slideshow
seekingalpha.com - August 11 at 7:59 AM
finance.yahoo.com logoIHS Markit Score Update: Drop in demand for ETFs holding Radius Health Inc is a negative sign for its shares
finance.yahoo.com - August 11 at 7:59 AM
finance.yahoo.com logoNew National Survey Reveals 82 Percent of Postmenopausal Women Miss Critical Connection Between Osteoporosis and Bone Fractures
finance.yahoo.com - August 11 at 7:59 AM
americanbankingnews.com logoCantor Fitzgerald Weighs in on Radius Health, Inc.'s FY2017 Earnings (NASDAQ:RDUS)
www.americanbankingnews.com - August 10 at 9:32 AM
americanbankingnews.com logoJefferies Group LLC Reiterates "Hold" Rating for Radius Health, Inc. (NASDAQ:RDUS)
www.americanbankingnews.com - August 9 at 11:26 AM
nasdaq.com logoRadius Health Announces Pricing of $300 Million of 3.00% Convertible Senior Notes due 2024 - Nasdaq
www.nasdaq.com - August 9 at 6:52 AM
nasdaq.com logoRSI Alert: Radius Health (RDUS) Now Oversold - Nasdaq
www.nasdaq.com - August 9 at 6:52 AM
finance.yahoo.com logoRadius Health Announces Pricing of $300 Million of 3.00% Convertible Senior Notes due 2024
finance.yahoo.com - August 9 at 6:52 AM
streetinsider.com logoRadius Health (RDUS) Plans Offering of $300M of Convertible Senior Notes due 2024 - StreetInsider.com
www.streetinsider.com - August 8 at 6:37 AM
streetinsider.com logoRadius Health (RDUS) Plans Offering of $300M of Convertible Senior Notes due 2024 - StreetInsider.com
www.streetinsider.com - August 8 at 6:37 AM
americanbankingnews.com logoRadius Health, Inc. (NASDAQ:RDUS) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 5 at 6:44 PM
finance.yahoo.com logoRadius (RDUS) Q2 Loss Wider than Expected on Higher Expenses
finance.yahoo.com - August 5 at 6:34 AM
seekingalpha.com logoRadius Health's (RDUS) CEO Jesper Høiland on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 7:30 AM
finance.yahoo.com logoInvestor Network: Radius Health Inc to Host Earnings Call
finance.yahoo.com - August 4 at 7:30 AM
finance.yahoo.com logoRadius Health Reports Second Quarter 2017 Financial and Operating Results and Provides Business Update
finance.yahoo.com - August 4 at 7:30 AM
finance.yahoo.com logoEdited Transcript of RDUS earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 7:30 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 28 at 10:49 AM
americanbankingnews.com logoJefferies Group Comments on Radius Health, Inc.'s Q3 2017 Earnings (RDUS)
www.americanbankingnews.com - July 26 at 9:48 AM
finance.yahoo.com logoWill Radius Health (RDUS) Disappoint this Earnings Season?
finance.yahoo.com - July 26 at 6:42 AM
benzinga.com logoApparently Fake Press Release Roils Radius Health Investors - Benzinga
www.benzinga.com - July 23 at 7:30 AM
streetinsider.com logoRadius Health (RDUS) Announces CHMP Has Issued Second Day-180 List of Outstanding Issues in Regulatory ... - StreetInsider.com
www.streetinsider.com - July 22 at 8:11 AM

Social

Chart

Radius Health (RDUS) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by MarketBeat.com Staff